NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

UNDERSTANDING SICKLE CELL DISEASE, ITS HISTORY, AND WILLFUL MISPERCEPTIONS

In a recent December 2024 interview on “The WAOK Morning Show,” 1380 Atlanta, Ga., Discussed sickle cell disease (SCD), highlighting the disease’s disproportionate impact on the Black community in the United States.

Understanding Sickle Cell Disease: Insights from a Vital Discussion Sickle cell disease (SCD) remains one of the most prevalent genetic health issues affecting people in the United States, with an estimated 100,000 individuals diagnosed, primarily within the Black community.

This paper reviews and assesses published clinical and demographic data that, in the aggregate, reveals that the entirety of present U.S. public health policy regarding SCD is seriously flawed. By ignoring SCD’s health disparity in the regulation of narcotic pain relievers, it is fundamentally biased, misdirected, and wrong on both facts and ethics.  

TO LISTEN TO THE FULL INTERVIEW, CLICK HERE.

The conversation emphasized the significant health disparities faced by SCD patients, including inadequate pain management due to systemic biases and limited access to quality care.

The high rates of hospitalization and substantial financial burden associated with SCD were also addressed, underscoring the urgent need for improved healthcare access and research funding.

Who is Glinda Dames-Fincher, and what role did she play in the WAOK Morning Show discussion?

The interview highlighted serious complications from SCD, such as stroke and organ damage, and the overall shorter life expectancy for those affected. Healthcare access disparity significantly impacts the lives of SCD patients, particularly within the Black community. Here are some key ways this disparity manifests:

●

Reduced Life Expectancy: Individuals with SCD face a life expectancy that is over 20 years shorter than the national average. This stark difference highlights the urgent need for better healthcare screenings and interventions tailored to this demographic, who often lack access to adequate medical care.

●

Pain Management Challenges and Stigma: Patients with SCD experience excruciating pain during acute pain crises. However, they frequently encounter skepticism and discrimination when seeking pain management, particularly when it comes to opioid medications. This can lead to delays in receiving crucial care, exacerbating their pain and suffering.

● Financial Burden and Resource Allocation: The treatment and management of SCD result in approximately 75,000 hospitalizations annually, costing the healthcare system an estimated $1.6 billion.

This raises concerns about the allocation of resources to address not only SCD itself but also the systemic inequities affecting healthcare outcomes for African American patients.

●

Limited Research and Funding: The healthcare system’s response to SCD has been inadequate. Many diseases, including sickle cell, do not receive the same level of research funding and support as other comparable conditions. This lack of investment further contributes to the health disparities faced by SCD patients.

The Centers for Disease Control and Prevention (CDC) reports that SCD disproportionately impacts non-Hispanic Black or African American populations, with the condition seen in 90% of diagnosed individuals.

DISINFORMATION: A MEDIA GRAVITATIONAL PULL TOWARD IGNORANCE AND DISPARITY IN PAIN CARE WORLDWIDE

Media’s embracement of disinformation and a gravitational pull toward ignorance of healthcare science and protocols are being put on trial; for more than a decade, the US and international public has been hearing that prescription opioid pain relievers are always and forever a “BAD THING.”

— and that doctors and Big Pharma companies are supposedly responsible for an epidemic of addiction and drug overdose-related deaths. 

In effect, if not intentionally, the de facto public health policy of the United States concerning the regulation of opioid pain relievers and of clinicians who employ them in pain management.

Tragically, it has become one of intentional restricting by the D.E.A. of the availability of critical and life-saving opioid therapies to patients and driving doctors who employ opioids out of practice or into prison – even when consistent with prescribing practices approved by the US Food and Drug Administration.

One point of concern raised in the discussion was the acute pain crisis that patients with sickle cell disease endure. These unpredictable episodes can arise suddenly and lead to excruciating pain due to the sickling of red blood cells, which obstructs blood flow and starves tissues of oxygen.

Yet, many SCD patients face challenges when seeking pain management. A significant aspect of the interview focused on the stigma surrounding the disease, especially when patients seek relief through emergency medical services.

SICKLE CELL AND THE WILLFUL MISPERCEPTION OF LAW ENFORCEMENT

There persists a troubling perception problem; patients frequently face skepticism regarding their need for pain medications like opioids. Such discrimination can lead to delays in urgent care, exacerbating the pain and suffering of patients.

Fincher’s conversation shed light on a concerning statistic that inadequate treatment of sickle cell disease (SCD) leads to high healthcare costs.

Approximately 75,000 hospitalizations occur annually due to SCD treatment and management. This results in an estimated $1.6 billion in healthcare costs.

This raises questions about resource allocation for addressing SCD and the systemic inequalities that negatively impact health outcomes for African American patients.

Moreover, the discussion emphasized the complications arising from sickle cell disease, including stroke, kidney and liver damage, as well as lung and heart complications. These serious health issues underline the imperative for comprehensive management plans, including access to regular screenings and personalized treatment options.

summary

In summary, healthcare access disparity for SCD patients results in a multitude of negative consequences, including reduced life expectancy, inadequate pain management, a significant financial burden, and limited research and funding. Addressing these disparities is crucial to improving the lives of those affected by this debilitating disease.

Ultimately, the discussion stressed the critical need to address healthcare inequities to improve outcomes for individuals with SCD.

DONATE LEGAL DEFENSE

OR SEND

TO CASH APP:$docnorm

ZELLE 3135103378

ALL WATCHED OVER BY MACHINES OF LOVING GRACE

BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!

FOR NOW, YOU ARE WITHIN

THE NORMS

To listen to the full interview, click the link above. Featured Image Photo Credit: Glinda Dames-Fincher, Angela Greene

REFERENCE AND BACKGROUND

Sickle Cell Disease FAQ

1. What is sickle cell disease (SCD)?

Sickle cell disease (SCD) is a genetic disorder primarily affecting red blood cells. In SCD, these cells become misshapen, taking on a crescent or sickle shape. This abnormal shape hinders their ability to flow smoothly through blood vessels, leading to blockages and oxygen deprivation in various tissues and organs.

2. Who is most commonly affected by SCD?

SCD disproportionately impacts the Black community, with approximately 90% of diagnosed individuals being of non-Hispanic Black or African American descent. This disparity highlights significant health inequities that need to be addressed.

3. What are the health consequences of SCD?

Individuals with SCD experience a range of serious health complications. Frequent and severe pain episodes, known as pain crises, are a hallmark of the disease. Additionally, SCD can lead to organ damage, including stroke, kidney and liver failure, and lung and heart complications. Tragically, life expectancy for those with SCD is significantly reduced, often by over 20 years compared to the national average.

4. What challenges do SCD patients face in accessing care?

Unfortunately, SCD patients often face numerous barriers in accessing appropriate care. These include limited access to specialized healthcare providers, inadequate pain management due to stigma and bias, and insufficient research funding compared to other diseases with comparable impact.

5. How does stigma impact SCD patients?

The stigma surrounding SCD, particularly concerning pain management, can have detrimental effects on patient care. Healthcare providers may exhibit skepticism toward patients’ pain reports, leading to delayed or inadequate treatment. This discriminatory behavior exacerbates suffering and undermines trust in the healthcare system.

6. What is being done to address the healthcare disparities associated with SCD?

Advocacy groups and healthcare professionals are working to raise awareness about SCD and advocate for improved access to quality care. Initiatives focus on early diagnosis through newborn screening, comprehensive disease management programs, and addressing social determinants of health that contribute to disparities.

7. What are the economic implications of SCD?

The treatment and management of SCD place a significant burden on the healthcare system, with an estimated annual cost of $1.6 billion. This high cost underscores the need to invest in preventive measures and comprehensive care models to improve patient outcomes and reduce long-term healthcare expenditures.

8. Where can I find more information about SCD?

For more information about SCD, you can visit the websites of reputable organizations such as the Centers for Disease Control and Prevention (CDC), the Sickle Cell Disease Association of America, and the National Heart, Lung, and Blood Institute. These resources offer comprehensive information about the disease, its treatment, and support services available to patients and their families.

Understanding Sickle Cell Disease: A Study Guide

Quiz

Instructions: Please answer the following questions in 2-3 sentences.

1. What population group is primarily affected by sickle cell disease (SCD) in the United States?
2. What is the average life expectancy difference between individuals with SCD and the general population?
3. Describe the phenomenon of a sickle cell pain crisis.
4. What is a significant challenge faced by SCD patients when seeking pain management?
5. How much does the US healthcare system spend annually on treating and managing SCD?
6. Apart from pain crises, name two other health complications that can arise from SCD.
7. What is a key concern regarding the research funding allocated to SCD?
8. Who is Glinda Dames-Fincher, and what role did she play in the WAOK Morning Show discussion?
9. Who hosted the WAOK Morning Show discussion on sickle cell disease?
10. What is the main point emphasized regarding the healthcare system’s response to SCD?

Answer Key

1. Sickle cell disease primarily affects the Black community in the United States, particularly non-Hispanic Black or African American individuals.
2. Individuals with SCD have a life expectancy that is approximately 20 years shorter than the national average.
3. A sickle cell pain crisis is an unpredictable episode of excruciating pain caused by the sickling of red blood cells. This sickling obstructs blood flow, leading to oxygen deprivation in tissues.
4. A significant challenge faced by SCD patients when seeking pain management is the stigma associated with the disease and skepticism regarding their need for pain medications, particularly opioids.
5. The treatment and management of SCD costs the US healthcare system an estimated $1.6 billion annually.
6. Two other health complications that can arise from SCD are stroke and organ damage, affecting organs like the kidneys, liver, lungs, and heart.
7. A key concern is that SCD often receives less research funding and support than other diseases with similar prevalence and impact.
8. Glinda Dames-Fincher is a Board Member and Sickle Cell Subcommittee Member who participated as a guest on the WAOK Morning Show to discuss the health disparities associated with SCD.
9. Angela Greene hosted the WAOK Morning Show discussion on sickle cell disease.
10. The main point emphasized is that the healthcare system’s response to SCD is often inadequate, with gaps in access to comprehensive management plans, regular screenings, and personalized treatment options.

Essay Questions

1. Discuss the socioeconomic and racial factors that contribute to the health disparities experienced by individuals with SCD.
2. Analyze the stigma surrounding SCD, particularly in the context of pain management, and its impact on patient care.
3. Evaluate the financial burden of SCD on the US healthcare system and propose strategies for resource allocation to address this challenge effectively.
4. Examine the importance of early diagnosis and comprehensive management plans in improving the quality of life for individuals with SCD.
5. Critically assess the role of public awareness campaigns and educational initiatives in dispelling misconceptions and promoting better understanding of SCD.

Glossary of Key Terms

• Sickle Cell Disease (SCD): A genetic blood disorder characterized by red blood cells that assume a sickle shape, leading to various health complications.
• Pain Crisis: An unpredictable episode of intense pain experienced by individuals with SCD due to blocked blood flow caused by sickled red blood cells.
• Stigma: Negative social attitudes and beliefs associated with a particular condition, leading to discrimination and prejudice.
• Health Disparities: Preventable differences in health outcomes and access to healthcare experienced by different population groups.
• Opioids: A class of strong pain-relieving medications often prescribed to manage severe pain, but their use can be controversial due to the potential for addiction.
• Comprehensive Management Plan: A personalized healthcare approach that includes regular screenings, preventive measures, and tailored treatment options to manage a chronic condition effectively.
• Systemic Inequities: Deeply rooted patterns of unfairness and bias within social systems that create and perpetuate disparities in various aspects of life, including healthcare.

Briefing Doc: Understanding Sickle Cell Disease – Key Takeaways from “The WAOK Morning Show”

Source: Interview with Glinda Dames-Fincher, Board Member & Sickle Cell Subcommittee Member, on “The WAOK Morning Show” with guest host Angela Greene.

Main Themes:

• Racial Disparities in Sickle Cell Disease: Sickle cell disease (SCD) disproportionately affects the Black community, leading to significant health disparities and shorter lifespans. This highlights the urgent need for improved healthcare access and tailored interventions.

“The Centers for Disease Control and Prevention (CDC) reports that SCD disproportionately impacts non-Hispanic Black or African American populations, with the condition seen in 90% of diagnosed individuals. This leads to alarming statistics: those living with SCD typically face life expectancies that are over 20 years shorter than the national average.”

• Stigma and Challenges in Pain Management: Patients with SCD often face skepticism and discrimination when seeking pain relief, particularly with opioid medications. This contributes to delays in care and exacerbates suffering.
• Economic Burden and Resource Allocation: SCD significantly burdens the healthcare system, costing an estimated $1.6 billion annually. This raises concerns about resource allocation and addressing systemic inequities in healthcare for African American patients.

“Fincher’s conversation shed light on a concerning statistic: the treatment and management of SCD result in approximately 75,000 hospitalizations annually, costing the healthcare system an estimated $1.6 billion.”

• Comprehensive Management and Research Needs: The discussion emphasized the need for comprehensive management plans, including regular screenings, personalized treatment options, and increased research funding to address the various complications arising from SCD.

Key Facts:

• Approximately 100,000 individuals in the United States are diagnosed with SCD.
• SCD is prevalent in 90% of non-Hispanic Black or African American individuals diagnosed with the disease.
• Life expectancy for individuals with SCD is over 20 years shorter than the national average.